Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carla Alpert"'
Autor:
Jiaqiang Cai, Bimjhana Bishwokarma, Dennis Leung, William J. Morris, Feroze Ujjainwalla, Candice Alleyne, Xiaoxing Du, Vincent J. Colandrea, Jennifer Piesvaux, Jianwu Bai, Liming Yang, Carla Alpert, Joseph M. Metzger, Vincenzo Pucci, Xiaofang Li, Jeffrey J. Hale, Dominique Stickens, Weiguo Quan, Byron G. DuBois, Rongqiang Liu, Mark Zielstorff, Chi-Sung Chiu, Christopher Joseph Sinz, Mangeng Cheng, Kallol Ray, Liping Wang, Ping Liu, Stella H. Vincent, Alejandro Crespo
Publikováno v:
ACS Medicinal Chemistry Letters. 9:1193-1198
[Image: see text] We report herein the design and synthesis of a series of orally active, liver-targeted hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors for the treatment of anemia. In order to mitigate the concerns for potential sys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d76215d13beffa00c0fc7a79f728fdec
https://doi.org/10.1021/acsmedchemlett.8b00274
https://doi.org/10.1021/acsmedchemlett.8b00274
Autor:
Kevin W. Johnson, Peter Fuller, Sujal V. Deshmukh, Fang He, Peter Goldenblatt, Lauren Dorosh, Hongbo Zeng, Jason D. Brubaker, Luis E. Torres, Tony Siu, Fiona Elwood, Charles A. Lesburg, Sangita B. Patel, Duan Liu, Elma Kadic, Christopher J. Dinsmore, Xavier Fradera, Lynsey Shaffer, Jonathan R. Young, Lily Y. Moy, Feng Shi, Carla Alpert, Joel A. Klappenbach, Joshua Close, Rafael Fernandez, Hongshi Yu, Nathan Bays, Dawn M. Mampreian
Publikováno v:
Journal of Medicinal Chemistry. 60:9676-9690
The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key paramete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6959a9f84f358dff1679660f1f0b87e
https://doi.org/10.1021/acs.jmedchem.7b01135
https://doi.org/10.1021/acs.jmedchem.7b01135
Autor:
Peter J. Dandliker, Hao Tang, Christopher J. Dinsmore, Chi-Sung Chiu, Fiona Elwood, Deborah Slipetz, Jennifer Piesvaux, Sujal V. Deshmukh, Ilona Kariv, Bo-Sheng Pan, Carla Alpert, Nathan Bays, Alan Byford, Alexey Rivkin, Peter Goldenblatt, Irena Ivanovska, Mark E. Scott, Joel A. Klappenbach, Hyun-Hee Lee, David J. Witter, Kalyan Chakravarthy, Lauren Dorosh, Yujie Qu, Brian Kraybill, Mark Zielstorff
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 361(2)
Reversible janus associated kinase (JAK) inhibitors such as tofacitinib and decernotinib block cytokine signaling and are efficacious in treating autoimmune diseases. However, therapeutic doses are limited due to inhibition of other JAK/signal transd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30dcce0e8183db5060a7c6ebeec57fe3
https://pubmed.ncbi.nlm.nih.gov/28193636
https://pubmed.ncbi.nlm.nih.gov/28193636